AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22115944 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 20
Study 19900070 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin 4 and 6 sulphate (CS)
Number of subjects: 0
Study 19900070 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 0
Study 17448179 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg
Number of subjects: 707
Study 17448179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 707
Study 15451915 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 77
Study 15451915 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 77
Study 15451915 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-sectional study
Number of subjects: 77
Study 11215606 — intervention group
Group type: EXPERIMENTAL
Intervention: Storage in saline-containing preservatives
Number of subjects: 44
Study 11215606 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 44
Study 11215606 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin and gentamicin
Number of subjects: 44
Study 10193296 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthpiece alone
Number of subjects: 20
Study 10193296 — intervention group
Group type: COMPARATOR
Intervention: Face mask
Number of subjects: 20
Study 10193296 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthpiece with noseclip
Number of subjects: 20
Study 10193296 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthpiece
Number of subjects: 20
Study 7532930 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon occluded arterial infusion (BOAI) treatment with cisplatin (100 mg/m2), aclacinomycin (30 mg/m2) and bleomycin (20 mg/m2)
Number of subjects: 19
Study 7532930 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (i.v.) administration of the same drugs (cisplatin, aclacinomycin, bleomycin)
Number of subjects: 19
Study 7532930 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon occluded arterial infusion (BOAI) treatment
Number of subjects: 19
Study 3284402 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA 5% cream
Number of subjects: 111
Study 3284402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 30567567 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discharge malaria chemoprevention (PMC) with dihydroartemesinin-piperaquine (DHP)
Number of subjects: 39
Study 30567567 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visit reminders by health surveillance assistants (HSAs)
Number of subjects: 39
Study 30567567 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing adherence to home visits
Number of subjects: 39
Study 27428338 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusions and erythropoietin (E)
Number of subjects: 80
Study 27428338 — intervention group
Group type: COMPARATOR
Intervention: Transfusions (T)
Number of subjects: 80
Study 25336121 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent dyadic intervention (exercise and support)
Number of subjects: 0
Study 24360107 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg parecoxib infusion 30 min preoperative and at 12, 24, 36, 48 h post-operation
Number of subjects: 80
Study 24360107 — intervention group
Group type: COMPARATOR
Intervention: 2 ml normal saline infusion (placebo)
Number of subjects: 80
Study 24360107 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg parecoxib infusion
Number of subjects: 80
Study 20689921 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV algorithm (NIV+)
Number of subjects: 65
Study 20689921 — intervention group
Group type: COMPARATOR
Intervention: No NIV algorithm (NIV0)
Number of subjects: 65
Study 18422481 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine (immediate or extended-release formulations)
Number of subjects: 0
Study 18422481 — intervention group
Group type: COMPARATOR
Intervention: Other antimuscarinic agents
Number of subjects: 0
Study 16810076 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg)
Number of subjects: 54
Study 16810076 — intervention group
Group type: COMPARATOR
Intervention: General measures
Number of subjects: 54
Study 16810076 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin
Number of subjects: 54
Study 16810076 — intervention group
Group type: COMPARATOR
Intervention: Fenofibrate and control groups (baseline CRP >or=3 mg/dL)
Number of subjects: 54
Study 16810076 — intervention group
Group type: COMPARATOR
Intervention: Fenofibrate and control groups (body weight changes)
Number of subjects: 54
Study 12454833 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy (HT)
Number of subjects: 126
Study 12454833 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 126
Study 12454833 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 126
Study 10511061 — intervention group
Group type: EXPERIMENTAL
Intervention: DX-9065a (0.625 to 30 mg, intravenously administered)
Number of subjects: 0
Study 7654164 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of trust and explanation
Number of subjects: 3563
Study 7654164 — intervention group
Group type: EXPERIMENTAL
Intervention: Trust only
Number of subjects: 3563
Study 7654164 — intervention group
Group type: EXPERIMENTAL
Intervention: Explanation only
Number of subjects: 3563
Study 7654164 — intervention group
Group type: COMPARATOR
Intervention: Neither trust nor explanation
Number of subjects: 3563
Study 2023202 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Number of subjects: 40
Study 2023202 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy
Number of subjects: 40
Study 7195414 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalidixic acid (1 g four times a day) for 14 days
Number of subjects: 81
Study 7195414 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin (500 mg four times a day) for 14 days
Number of subjects: 81
Study 7195414 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin (500 mg four times a day) for 3 days
Number of subjects: 81
Study 7195414 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalidixic acid (1 g four times a day) for 3 days
Number of subjects: 81
Study 30782673 — intervention group
Group type: EXPERIMENTAL
Intervention: Wedge‐shaped excision and modified buried vertical mattress suture (WE‐MBVMS)
Number of subjects: 78
Study 30782673 — intervention group
Group type: COMPARATOR
Intervention: Buried intradermal suture (BIS)
Number of subjects: 78
Study 28592063 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium (0.15 mg/kg) with end-tidal sevoflurane concentration at 2.5%
Number of subjects: 45
Study 28592063 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium (0.15 mg/kg) with end-tidal sevoflurane concentration at 3.0%
Number of subjects: 45
Study 28592063 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium (0.15 mg/kg) with end-tidal sevoflurane concentration at 3.5%
Number of subjects: 45
Study 25379637 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (Se) supplementation
Number of subjects: 0
Study 25379637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22505570 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle + Stress
Number of subjects: 44
Study 22505570 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle Alone
Number of subjects: 44
Study 22105407 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving simulator performance in AD subjects (CDR 0.5 and CDR 1)
Number of subjects: 80
Study 22105407 — intervention group
Group type: COMPARATOR
Intervention: Driving simulator performance in cognitively normal elderly controls
Number of subjects: 80
Study 19015870 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine
Number of subjects: 9
Study 19015870 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAAs
Number of subjects: 9
Study 19015870 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine
Number of subjects: 9
Study 19015870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 17987229 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib
Number of subjects: 150
Study 17987229 — intervention group
Group type: COMPARATOR
Intervention: DTPa-IPV/Hib + HBV
Number of subjects: 150
Study 15064595 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-loop feedback plus reinforcement intervention
Number of subjects: 18
Study 15064595 — intervention group
Group type: COMPARATOR
Intervention: No feedback, no reinforcement control
Number of subjects: 18
Study 11465619 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (target concentration, 1.5 microg/ml)
Number of subjects: 8
Study 11465619 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil (12.5 microg/kg intravenous followed by 25 microg.kg(‐1).h(‐1))
Number of subjects: 8
Study 10223218 — intervention group
Group type: EXPERIMENTAL
Intervention: Sero Strip HIV 1/2 rapid test
Number of subjects: 200
Study 7604347 — intervention group
Group type: COMPARATOR
Intervention: Saline injection alone
Number of subjects: 39
Study 7604347 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemonucleolysis alone
Number of subjects: 39
Study 7604347 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminectomy for failed intradiscal injection
Number of subjects: 39
Study 2196144 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (20 mg) administered twice daily for 4 weeks
Number of subjects: 10
Study 517713 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 0.6 mg and Neostigmine 2.5 mg i.v.
Number of subjects: 20
Study 517713 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 0.6 mg and Neostigmine 5 mg i.v.
Number of subjects: 20
Study 31218649 — intervention group
Group type: EXPERIMENTAL
Intervention: Bemiparin
Number of subjects: 89
Study 30325613 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial urethral sphincter (AUS) implant 'BR - SL - AS - 904'
Number of subjects: 15
Study 27387696 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low-Calorie Diet (VLCD) for 2 weeks
Number of subjects: 15
Study 27387696 — intervention group
Group type: COMPARATOR
Intervention: Normal Diet for 2 weeks
Number of subjects: 15
Study 27387696 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups postoperatively (2 weeks and 1 year)
Number of subjects: 15
Study 27387696 — intervention group
Group type: EXPERIMENTAL
Intervention: VLCD
Number of subjects: 15
Study 25276755 — intervention group
Group type: EXPERIMENTAL
Intervention: Triggers modifying educational intervention (5 weeks, nurse-led)
Number of subjects: 60
Study 25276755 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 60
Study 22820475 — intervention group
Group type: COMPARATOR
Intervention: No DE Signs (NDES)
Number of subjects: 226
Study 20233182 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐(+)‐MA 0.25 mg kg(‐1)
Number of subjects: 12
Study 20233182 — intervention group
Group type: EXPERIMENTAL
Intervention: R‐(‐)‐MA 0.25 mg kg(‐1)
Number of subjects: 12
Study 20233182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 18565951 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated protein C (APC) 24 microg/kg/h for 96 h
Number of subjects: 75
Study 18565951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 15939857 — intervention group
Group type: EXPERIMENTAL
Intervention: Children wishing to be thinner at age 8 years
Number of subjects: 435
Study 15939857 — intervention group
Group type: COMPARATOR
Intervention: Children satisfied with their size
Number of subjects: 435
Study 15939857 — intervention group
Group type: COMPARATOR
Intervention: Children wishing to look heavier
Number of subjects: 435
Study 14683659 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir-lamivudine-tenofovir combination treatment
Number of subjects: 8
Study 10383524 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 1200 mg/day for 10 days
Number of subjects: 1246
Study 10383524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1246
Study 8522064 — intervention group
Group type: EXPERIMENTAL
Intervention: African-American race
Number of subjects: 453
Study 8522064 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 453
Study 8522064 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 453
Study 8522064 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline resting systolic blood pressure
Number of subjects: 453
Study 8522064 — intervention group
Group type: EXPERIMENTAL
Intervention: Pack-years smoking
Number of subjects: 453
Study 1497770 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose cefuroxim (Zinacef)
Number of subjects: 106
Study 1497770 — intervention group
Group type: COMPARATOR
Intervention: Three-shot, 24-hour regimen of cefuroxim (Zinacef)
Number of subjects: 106
Study 6836645 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine infusion (1 microgram kg-1 min-1)
Number of subjects: 16
Study 2859782 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily treatment (n = 97)
Number of subjects: 192
Study 2859782 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily treatment (n = 47)
Number of subjects: 192
Study 2859782 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily (n = 48)
Number of subjects: 192
Study 30051198 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide-LAR (40 mg/4 weeks)
Number of subjects: 35
Study 27966503 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 5% potassium nitrate
Number of subjects: 160
Study 27966503 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 5% CSPS (NovaMin)
Number of subjects: 160
Study 27966503 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 10% strontium chloride
Number of subjects: 160
Study 27966503 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal formulation toothpaste
Number of subjects: 160
Study 24730399 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tetracaine hydrochloride 1%
Number of subjects: 116
Study 24730399 — intervention group
Group type: COMPARATOR
Intervention: Saline eye drops
Number of subjects: 116
Study 22467148 — intervention group
Group type: EXPERIMENTAL
Intervention: PlasmaJet (PJ)
Number of subjects: 15
Study 22467148 — intervention group
Group type: COMPARATOR
Intervention: Helica thermal coagulator (HTC)
Number of subjects: 15
Study 20124059 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive approach
Number of subjects: 20
Study 20124059 — intervention group
Group type: COMPARATOR
Intervention: Standard approach
Number of subjects: 20
Study 20124059 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 18582370 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus acupuncture
Number of subjects: 386
Study 18582370 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment plus specific stabilising exercises
Number of subjects: 386
Study 18582370 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 386
Study 16042730 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel midstream urine-collection device (UCD)
Number of subjects: 2823
Study 12564745 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-melting tablet
Number of subjects: 30
Study 12564745 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent tablet
Number of subjects: 30
Study 12564745 — intervention group
Group type: COMPARATOR
Intervention: Soft gelatin preparation
Number of subjects: 30
Study 12564745 — intervention group
Group type: COMPARATOR
Intervention: Powder-filled hard shell preparation
Number of subjects: 30
Study 11002954 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol 400 microg
Number of subjects: 401
Study 11002954 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular oxytocin 10 IU
Number of subjects: 401
Study 9242092 — intervention group
Group type: EXPERIMENTAL
Intervention: Subepithelial connective tissue grafts (SCTG)
Number of subjects: 36
Study 9242092 — intervention group
Group type: COMPARATOR
Intervention: Guided tissue regeneration (GTR)
Number of subjects: 36
Study 1346558 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (30 mg 3 times daily)
Number of subjects: 8
Study 1346558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1346558 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Number of subjects: 8
Study 6383990 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 0
Study 6383990 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 0
Study 30577902 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone treatment in jail-based program
Number of subjects: 520
Study 30577902 — intervention group
Group type: COMPARATOR
Intervention: Methadone treatment in community programs
Number of subjects: 520
Study 30069587 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 300 mg/day
Number of subjects: 431
Study 30069587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431
Study 26822428 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (control phase)
Number of subjects: 0
Study 26822428 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusion
Number of subjects: 0
Study 25164906 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tVNS (200 μs, 30 Hz; n = 34)
Number of subjects: 48
Study 25164906 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (n = 14)
Number of subjects: 48
Study 21960289 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgE (sIgE)
Number of subjects: 353
Study 21960289 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT)
Number of subjects: 353
Study 21960289 — intervention group
Group type: EXPERIMENTAL
Intervention: Total IgE concentration
Number of subjects: 353
Study 18304540 — intervention group
Group type: EXPERIMENTAL
Intervention: TCM-199
Number of subjects: 13
Study 18304540 — intervention group
Group type: COMPARATOR
Intervention: HTF
Number of subjects: 13
Study 16914240 — intervention group
Group type: EXPERIMENTAL
Intervention: GLURP(85‐213) with Aluminum Hydroxide (Alum)
Number of subjects: 36
Study 16914240 — intervention group
Group type: EXPERIMENTAL
Intervention: GLURP(85‐213) with Montanide ISA 720 (ISA)
Number of subjects: 36
Study 16914240 — intervention group
Group type: EXPERIMENTAL
Intervention: GLURP(85‐213) (10, 30, or 100 microg)
Number of subjects: 36
Study 16914240 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 36
Study 15895318 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (FIO2 = 13% O2) during moderate intensity exercise (80% of FIO2-specific VT)
Number of subjects: 27
Study 15895318 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (FIO2 = 13% O2) during heavy intensity exercise
Number of subjects: 27
Study 15895318 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (FIO2 = 13% O2) in endurance athletes
Number of subjects: 27
Study 15895318 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (FIO2 = 13% O2) in sprint trained subjects
Number of subjects: 27
Study 15895318 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (FIO2 = 13% O2) in untrained controls
Number of subjects: 27
Study 15895318 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (FIO2 = 21% O2)
Number of subjects: 27
Study 12473544 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow-derived progenitor cells
Number of subjects: 20
Study 12473544 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating blood-derived progenitor cells
Number of subjects: 20
Study 12473544 — intervention group
Group type: COMPARATOR
Intervention: Progenitor cells (both types)
Number of subjects: 20
Study 10389558 — intervention group
Group type: EXPERIMENTAL
Intervention: Diprifusor TCI
Number of subjects: 123
Study 10389558 — intervention group
Group type: COMPARATOR
Intervention: MCI
Number of subjects: 123
Study 10389558 — intervention group
Group type: COMPARATOR
Intervention: Diprifusor TCI and MCI
Number of subjects: 123
Study 8897055 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanning laser polarimetry (Nerve Fiber Analyzer type 1, software version 1.6)
Number of subjects: 56
Study 8897055 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratios of the measured values
Number of subjects: 56
Study 1900007 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA
Number of subjects: 319
Study 1900007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319
Study 6203024 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal therapy (chemotherapy + multiple fractionated radiation therapy)
Number of subjects: 58
Study 6203024 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple daily fractionated radiation therapy
Number of subjects: 58
Study 6203024 — intervention group
Group type: COMPARATOR
Intervention: Single-modality therapy (chemotherapy alone or radiation therapy alone)
Number of subjects: 58
Study 30659041 — intervention group
Group type: EXPERIMENTAL
Intervention: TN‐TC11LM (THC:CBD in 1:1 ratio) capsules daily for 12 weeks
Number of subjects: 26
Study 30659041 — intervention group
Group type: EXPERIMENTAL
Intervention: TN‐TC19LM (THC:CBD in 1:9 ratio) capsules daily for 12 weeks
Number of subjects: 26
Study 30659041 — intervention group
Group type: EXPERIMENTAL
Intervention: TN‐TC11LM and TN‐TC19LM capsules
Number of subjects: 26
Study 29437074 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (self-administered sedation)
Number of subjects: 1
Study 27798759 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline soluble ST2 (sST2) levels
Number of subjects: 684
Study 27798759 — intervention group
Group type: COMPARATOR
Intervention: Cardiac resynchronization therapy defibrillators (CRT-D)
Number of subjects: 684
Study 27798759 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial assessment of soluble ST2 (sST2)
Number of subjects: 684
Study 25541552 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressed breast milk (EBM) + Standard practice
Number of subjects: 0
Study 21745325 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 36
Study 21745325 — intervention group
Group type: COMPARATOR
Intervention: Conventional rotative instruments
Number of subjects: 36